Zydus Lifesciences to launch Phase 2 Parkinson’s disease trial of ZYIL1
Zydus Lifesciences Limited, a globally recognized pharmaceutical company, has recently obtained the USFDA's approval to commence Phase II clinical study of its NLRP3 inhibitor, ZYIL1, ... Read More
Zydus advances PCSK9 inhibitor with Phase I clinical study approval
Zydus, a global pharmaceutical company, has secured permission from CDSCO, India, to kickstart the Phase I clinical study of its groundbreaking PCSK9 inhibitor. This Phase ... Read More
Zydus Lifesciences initiates phase 4 trial for Saroglitazar Mg in NAFLD
Zydus Lifesciences, an Indian life sciences company, has announced the commencement of Phase IV Real World Data Registry trial "EVIDENCES-XI" for Saroglitazar Magnesium (Mg) in ... Read More
Cadila Healthcare gets FDA nod for phase 2(b)/3 trial of saroglitazar magnesium
Cadila Healthcare (Zydus Cadilla) said that it has obtained permission from the US Food and Drug Administration (FDA) to launch the phase 2(b)/3 clinical trial ... Read More
Zydus Cadila begins EVIDENCES-X phase 2b NASH trial of Saroglitazar Mg
Zydus Cadila (Cadila Healthcare) has dosed the first patient in the EVIDENCES-X phase 2b clinical trial of Saroglitazar Magnesium (Saroglitazar Mg) in non-alcoholic steatohepatitis (NASH). ... Read More
Zydus Cadila gets EUA for ZyCoV-D vaccine for Covid-19 in India
Zydus Cadila (Cadila Healthcare) said that it has secured the emergency use authorization (EUA) from the Drug Controller General of India (DCGI) for ZyCoV-D vaccine ... Read More